\n<\/p>\n
Verilerin \u00f6zetine g\u00f6re, 75 miligram Trevogrumab’\u0131n Semaglutid’e eklenmesi, 52. haftada Semaglutid tek ba\u015f\u0131na kullan\u0131ld\u0131\u011f\u0131nda meydana gelen kas k\u00fctlesi kayb\u0131n\u0131n y\u00fczde 70’inden fazlas\u0131n\u0131 \u00f6nledi.<\/p>\n
\u00a0<\/p>\n
\u00c7al\u0131\u015fman\u0131n bir b\u00f6l\u00fcm\u00fcnde yaln\u0131zca Semaglutid kullanan hastalar, 26 haftada ya\u011fs\u0131z kas k\u00fctlelerinin y\u00fczde 6,7’sini kaybetti. 75 miligram Trevogrumab da kullanan hastalarda ise kas k\u00fctlesi kayb\u0131 y\u00fczde 3,3’te kald\u0131. 25 miligram Trevogrumab kullan\u0131lan kombinasyonda da kas k\u00fctlesi kayb\u0131 y\u00fczde 4,7 oldu.<\/p>\n
\u00a0<\/p>\n
Hastalar Semaglutidi b\u0131rakt\u0131\u011f\u0131nda ancak Trevogrumab kullanmaya devam etti\u011finde, kas k\u00fctlelerinin \u00e7al\u0131\u015fmaya ba\u015flamadan \u00f6nceki seviyesine geri d\u00f6nd\u00fc\u011f\u00fc g\u00f6r\u00fcld\u00fc. \u015eirket, bunun ilac\u0131n kaybedilen kaslar\u0131n yeniden kazan\u0131lmas\u0131na yard\u0131mc\u0131 olabilece\u011fini g\u00f6sterdi\u011fini belirtti.<\/p>\n
\u00a0<\/p>\n
Regeneron y\u00f6neticisi Boaz Hirshberg, “GLP-1 kullanan hastalar\u0131n kilolar\u0131n\u0131n yakla\u015f\u0131k y\u00fczde 30’unu ya\u011fs\u0131z kas k\u00fctlesi \u015feklinde kaybetti\u011fini ve Trevogrumab ile bunu \u00f6nleyebildi\u011fimizi do\u011frulad\u0131k.” dedi. Hirshberg, tedavinin en b\u00fcy\u00fck faydas\u0131n\u0131n ba\u015flang\u0131\u00e7ta daha d\u00fc\u015f\u00fck kas k\u00fctlesine sahip hastalarda g\u00f6r\u00fclebilece\u011fini belirtti.<\/p>\n<\/div>\n